TY - JOUR
T1 - Prevention of cytarabine-induced kerato-conjunctivitis by eye rinse in patients receiving high-dose cytarabine and total body irradiation as a conditioning for hematopoietic stem cell transplantation
AU - Mori, Takehiko
AU - Kato, Jun
AU - Yamane, Akiko
AU - Aisa, Yoshinobu
AU - Kawata, Yusuke
AU - Ichimura, Mayu
AU - Tsuneyama, Chiaki
AU - Yashima, Tomoko
AU - Ogawa, Yoko
AU - Tsubota, Kazuo
AU - Shigematsu, Naoyuki
AU - Shimizu, Takayuki
AU - Okamoto, Shinichiro
PY - 2011/9
Y1 - 2011/9
N2 - We previously reported a high incidence of kerato-conjunctivitis in patients receiving high-dose cytarabine following total body irradiation (TBI) as a conditioning for hematopoietic stem cell transplantation (HSCT) even on prophylaxis with topical corticosteroid. This study aimed to evaluate whether addition of eye rinse, which was designed to remove cytarabine from ocular surface, further reduces the incidence of kerato-conjunctivitis in the same setting. Seventy-six patients receiving cytarabine at a dose of 3 g/m 2 every 12 h for 4 days after receiving TBI (12 Gy) as conditioning for HSCT were evaluated. All patients received betamethasone sodium phosphate eye drops. Twenty-three patients were further instructed to rinse their eyes with sterile saline every 10-15 min during and for two additional hours after the completion of each cytarabine infusion. Among 23 patients with eye rinse, Grades 2-3 and 1-3 kerato-conjunctivitis were observed in 4 (17.4%) and 5 patients (21.7%), respectively. These incidences were significantly lower than those [35 (66.0%) and 41 (77.4%)] observed in 53 patients without eye rinse (P<0.001 and P<0.00001, respectively). These results strongly suggest that eye rinse effectively reduces the incidence and severity of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI.
AB - We previously reported a high incidence of kerato-conjunctivitis in patients receiving high-dose cytarabine following total body irradiation (TBI) as a conditioning for hematopoietic stem cell transplantation (HSCT) even on prophylaxis with topical corticosteroid. This study aimed to evaluate whether addition of eye rinse, which was designed to remove cytarabine from ocular surface, further reduces the incidence of kerato-conjunctivitis in the same setting. Seventy-six patients receiving cytarabine at a dose of 3 g/m 2 every 12 h for 4 days after receiving TBI (12 Gy) as conditioning for HSCT were evaluated. All patients received betamethasone sodium phosphate eye drops. Twenty-three patients were further instructed to rinse their eyes with sterile saline every 10-15 min during and for two additional hours after the completion of each cytarabine infusion. Among 23 patients with eye rinse, Grades 2-3 and 1-3 kerato-conjunctivitis were observed in 4 (17.4%) and 5 patients (21.7%), respectively. These incidences were significantly lower than those [35 (66.0%) and 41 (77.4%)] observed in 53 patients without eye rinse (P<0.001 and P<0.00001, respectively). These results strongly suggest that eye rinse effectively reduces the incidence and severity of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI.
KW - Eye rinse
KW - High-dose cytarabine
KW - Kerato-conjunctivitis
KW - Topical corticosteroid
KW - Total body irradiation
UR - http://www.scopus.com/inward/record.url?scp=80855137978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80855137978&partnerID=8YFLogxK
U2 - 10.1007/s12185-011-0912-x
DO - 10.1007/s12185-011-0912-x
M3 - Article
C2 - 21853271
AN - SCOPUS:80855137978
SN - 0925-5710
VL - 94
SP - 261
EP - 265
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 3
ER -